



### Original Investigation | Oncology

# Effect of Cancer Pain Guideline Implementation on Pain Outcomes **Among Adult Outpatients With Cancer-Related Pain** A Stepped Wedge Cluster Randomized Trial

Melanie R. Lovell, PhD; Jane L. Phillips, PhD; Tim Luckett, PhD; Lawrence Lam, PhD; Frances M. Boyle, PhD; Patricia M. Davidson, PhD; Seong L. Cheah, PhD; Nicola McCaffrey, PhD; David C. Currow, PhD; Tim Shaw, PhD; Annmarie Hosie, PhD; Bogda Koczwara, MBioethics; Stephen Clarke, PhD; Jessica Lee, MBBS; Martin R. Stockler, MBBS; Caitlin Sheehan, MBBS; Odette Spruijt, PhD; Katherine Allsopp, MBBS; Alexandra Clinch, MBBS; Katherine Clark, PhD; Alison Read, RN; Meera Agar, PhD

# **Abstract**

**IMPORTANCE** An evidence-practice gap exists for cancer pain management, and cancer pain remains prevalent and disabling.

**OBJECTIVES** To evaluate the capacity of 3 cancer pain guideline implementation strategies to improve pain-related outcomes for patients attending oncology and palliative care outpatient services.

DESIGN, SETTING, AND PARTICIPANTS A pragmatic, stepped wedge, cluster-randomized, nonblinded, clinical trial was conducted between 2014 and 2019. The clusters were cancer centers in Australia providing oncology and palliative care outpatient clinics. Participants included a consecutive cohort of adult outpatients with advanced cancer and a worst pain severity score of 2 or more out of 10 on a numeric rating scale (NRS). Data were collected between August 2015 and May 2019. Data were analyzed July to October 2019 and reanalyzed November to December 2021.

INTERVENTIONS Guideline implementation strategies at the cluster, health professional, and patient levels introduced with the support of a clinical champion.

MAIN OUTCOMES AND MEASURES The primary measure of effect was the percentage of participants initially screened as having moderate to severe worst pain (NRS  $\geq$  5) who experienced a clinically important improvement of 30% or more 1 week later. Secondary outcomes included mean average pain, patient empowerment, fidelity to the intervention, and quality of life and were measured in all participants with a pain score of 2 or more 10 at weeks 1, 2, and 4.

RESULTS Of 8099 patients screened at 6 clusters, 1564 were eligible, and 359 were recruited during the control phase (mean [SD] age, 64.2 [12.1] years; 196 men [55%]) and 329 during the intervention phase (mean [SD] age, 63.6 [12.7] years; 155 men [47%]), with no significant differences between phases on baseline measures. The mean (SD) baseline worst pain scores were 5.0 (2.6) and 4.9 (2.6) for control and intervention phases, respectively. The mean (SD) baseline average pain scores were 3.5 (2.1) for both groups. For the primary outcome, the proportions of participants with a 30% or greater reduction in a pain score of 5 or more of 10 at baseline were similar in the control and intervention phases (31 of 280 participants [11.9%] vs 30 of 264 participants [11.8%]; OR, 1.12; 95% CI, 0.79-1.60; P = .51). No significant differences were found in secondary outcomes between phases. Fidelity to the intervention was low.

(continued)

### **Key Points**

Question Can guideline implementation strategies improve pain outcomes in adult outpatients with cancerrelated pain?

Findings In this cluster-randomized trial of 544 patients, a suite of implementation strategies comprising audit and feedback, clinician-spaced education, and a patient selfmanagement resource was evaluated. There was no statistical difference in pain-related outcomes, and fidelity, which was measured by uptake of the 3 implementation strategies, was lower than expected.

**Meaning** These findings suggest that cancer pain screening and subsequent management will need to be highly valued, supported by adequate resources embedded within the clinical workflow, and supported by electronic data systems to be successful.

# Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

**CONCLUSIONS AND RELEVANCE** A suite of implementation strategies was insufficient to improve pain-related outcomes for outpatients with cancer-related pain. Further evaluation is needed to determine the required clinical resources needed to enable wide-scale uptake of the fundamental elements of cancer pain care. Ongoing quality improvement activities should be supported to improve sustainability.

JAMA Network Open. 2022;5(2):e220060. doi:10.1001/jamanetworkopen.2022.0060

# Introduction

Cancer pain is a prevalent, disabling, and distressing symptom. The prevalence of pain of moderate or severe intensity is greater than 50% in patients with advanced cancer and is undertreated in around one-third of individuals. Beyond personal suffering for individuals and their families, untreated pain is associated with higher health care use. 2-4 Clinical practice guidelines provide evidence-based recommendations for pain management; however, adoption and adherence are suboptimal. A greater focus on strategies to foster implementation is needed. Barriers to guideline implementation exist at patient, health professional, and health service levels suggesting the need for multifaceted strategies. 7-9

Effective cancer pain assessment and management requires patient self-report using patient-reported outcome measures (PROMs) and adherence to management plans; health professionals with the commitment, knowledge, and skills to manage pain; and health services to provide a method of screening to identify and monitor symptoms. <sup>6,10</sup> Screening for pain in cancer outpatients has been shown to improve quality of care and, more recently, pain-related outcomes. <sup>11</sup> However, as with guidelines, clinicians are unlikely to use symptom screening to inform pain management unless they are motivated and supported by their health systems either locally, regionally, or nationally. <sup>12</sup> Other strategies known to improve pain outcomes include patient education <sup>8,13</sup> and health professional education. <sup>14,15</sup> Audit and feedback have proven effects on professional practice and health care outcomes. <sup>16</sup> Implementation of cancer pain assessment and management improvement strategies has been shown to be effective in inpatient settings. <sup>17</sup> However, implementation has been met with variable success in the ambulatory care setting. <sup>18,19</sup>

This study's primary aim was to measure if the intervention resulted in a 30% improvement in pain score in adults attending oncology or palliative care outpatient clinics with a pain Numeric Rating Scale (NRS) score of 5 or more. Four secondary aims were included to evaluate the capacity of 3 guideline implementation strategies compared with standard care in people screened for cancer pain alone. First, we evaluated the implementation strategies' ability to reduce the mean worst pain and mean average pain severity throughout the past 24 hours across patients screened as having clinically relevant (ie, NRS  $\geq$  2) or moderate to severe (ie, NRS  $\geq$  5) worst pain from the time of screening to 1, 2, and 4 weeks later by an SD of 0.5.20 Second, we evaluated their ability to find a between-phase difference in patient empowerment as measured by 0.5-SD difference on the Health Education Impact Questionnaire (heiQ), <sup>21</sup> mean patient quality of life (QOL), as measured by a difference of 0.5 SD on the European Organisation for Research and Treatment of Cancer Palliative Care (EORTC QLQ C15-PAL), <sup>22</sup> and difference in the experiences of unpaid carers of participating patients, as measured by a 0.5-SD difference on the Carer Experience Scale (CES)<sup>23</sup> at 2 and 4 weeks after screening. Third, we evaluated the implementation strategies' capacity to assess the costeffectiveness of the 3 guideline implementation strategies based on incremental cost per additional responder on the primary outcome. Fourth, we assessed their fidelity to the intervention. The current article reports results relating to the primary aim and the first and third of the secondary aims.

### Methods

This stepped-wedge, cluster-randomized trial was reported according to the Consolidated Standards of Reporting Trials Extension (CONSORT Extension) reporting guideline.<sup>24</sup> Ethical approval was granted by the human research ethics committee of the Southwestern Sydney Local Health District. Following commencement of the trial, an approved amendment allowed for patients to provide verbal consent rather than written consent to ensure timely collection of data at week 1. The methods are reported in Luckett et al<sup>25</sup> and summarized below. The trial protocol can be found in Supplement 1.

### **Study Design and Participants**

### Design

A stepped wedge, cluster-randomized trial approach was taken in which clusters were randomized to commence the intervention at different times following an initial control period in which outcomes were measured for usual care. A training phase enabled the transition from control to intervention, during which recruitment and measurement were placed on hold.

### **Participants and Setting**

The clusters were cancer centers, which provided medical and radiation oncology, and palliative care clinics. Purposive sampling was used to ensure that a range of metropolitan and regional centers from various states or territories across Australia were represented. Eligible participants were adults with advanced cancer and a worst pain severity of 2 or more out of 10 on an NRS, who were able to complete the NRS in 1 of the 6 most frequent languages spoken in Australia (ie, English, Italian, Greek, Arabic, Mandarin, or Vietnamese) who did not opt out. Caregivers were eligible if they were identified by a patient, provided consent, and had sufficient English to give informed consent and complete the measures. Staff were eligible if they were employed permanently, either full- or parttime, and provided care or administrative support to patients at a participating cancer center.

# Recruitment

Our study design enabled the intervention to target practice change at the center level without risking contamination between phases and control for practice variation between centers. Centers were randomized to transition one at a time. Each patient was recruited to participate in either the control or intervention phase, but not both, thus, samples differed between phases and consent was obtained. The time between each step was not predetermined by dates but rather by the readiness of centers to commence and the speed they recruited to the target sample size. A sustainability phase was also included in the design wherein medical records of patients screened as having severe pain (≥7 NRS) were audited at 3-month intervals from the end of the intervention phase to the end of the study period to assess whether adherence to guidelines for pain screening, assessment, and management were continued.

### Randomization

The order in which each center moved from control to intervention phase was randomly allocated by a computer algorithm performed by the study statistician. Allocation of clusters could not be concealed from clinicians and managers. Blinding for center staff and the project team collecting data was not possible. However, information for patients provided only general information about the aims of the study, not the specifics of the design and intervention. Patients were allocated based on whether the center they attended was in the control or intervention phase at the time they were first screened as having worst pain rated 2 or more on the NRS.

### **Treatment Allocation**

### Control

A paper-based screening system was implemented at each center whereby all patients were requested to complete an NRS for worst pain and average pain during the past 24 hours on each visit. Pain screening was administered to patients in the waiting room either by administrative personnel or nursing staff, depending on the center. Each center provided usual care, as per local practice. No attempt was made to encourage or discourage pain screening data being used to inform patient consultations.

### **Training and Intervention**

During the training phase, center clinicians were given an overview of the guidelines and implementation resources by a local clinical champion with support from the project team. A system was established at each center to enable screening results to be communicated to the physician to inform the consultation. Guideline implementation strategies developed using a conceptual framework (Michie Behavior Change Wheel)<sup>26</sup> included: (1) audit of adherence to 6 key guideline recommendations and feedback delivered in 1 to 2 cycles; (2) health professional education using email-administered spaced education via the Qstream platform;<sup>27</sup> and (3) an education booklet and a patient self-management resource. These strategies have a positive impact when implementing guidelines either in cancer pain or other clinical contexts but have never been tested in combination.

### **Outcomes**

Patient-reported outcome measures were obtained by researchers contacting participants by phone who scored 2 or more on either NRS at the time of screening. If the participant could not be reached after 3 attempts on 3 consecutive days, their data were categorized as missing for that time point.

The primary study outcome was the percentage of patients at the cluster level screened with a score of 5 or more out of 10 on a worst pain NRS with a pain reduction of 30% from the initial NRS at week 1. Thirty percent was selected based on the US Food and Drug Administration recommendations, which indicate that measurement of minimal clinically important difference should take account of the baseline score. <sup>28</sup> Pain rated as 5 on the NRS was selected as an established threshold for moderate pain. <sup>29</sup> Secondary outcomes were collected via telephone at weeks 1, 2, and 4 after screening and consisted of worst pain and average pain NRS, patient empowerment heiQ, <sup>21</sup> carer experience with the CES<sup>23</sup>, and patient QOL using the EORTC QLQ-C15-PAL. <sup>22</sup> Data collection deviated from the protocol by collecting only the following domains of the heiQ after the whole measure was found too burdensome for patients: social integration and support, health service navigation, constructive attitudes and approaches, and skill and technique acquisition.

Fidelity was assessed for each part of the intervention. The number of patients receiving written pain education materials was assessed by asking the patient over the telephone at week 1 if they had received them. This was implemented after the first site completed and hence, we have data for 5 sites only. The clinicians' completion of the online spaced education module was measured via the administering platform of QStream platform. The number of audit and feedback rounds was counted.

# **Statistical Analysis**

We used a carefully designed computer simulation, allowing for 20% dropout by both centers and patients, to estimate statistical power. Drawing on data from 1612 consecutive patients, <sup>30</sup> outcome data were generated to mimic the pain scores we expected to see in the presenting population. Data were analyzed using Stata version 17 BE (StataCorp). Sample size required was 82 at 6 sites totaling 492. The sample size calculation was based on the statistical approach for analyses being the Generalized Linear Mixed Model with a 2-tailed test. Pearson  $\chi^2$  tests or the Student t test were used to compare baseline patients' characteristics between control and intervention phases. To cater for

the cluster effect in the primary outcome measure, the generalized linear mixed model with a binary outcome was applied to examine the differences in proportions of pain score reduction by 30% between phases with adjustment for possible confounding variables, such as age, gender, cancer type, Qstream, information pack, audit cycles, and the time spent in each phase. A similar analytical approach was adopted to analyze all secondary outcome measures with adaptation for continuous variables. For testing of the hypothesis, a 2-tailed error rate of 5% was used.

A statistically significant level of P < .05 was used for all tests. Data were collected between August 2015 and May 2019. Data were analyzed July 2019 to October 2019 and data were reanalyzed in November and December 2021.

### Results

# **Participants**

This study included 8 centers, 2 regional and 6 metropolitan, across 3 Australian states between August 2015 and May 2019. Two regional centers withdrew after completing the control phase because of a lack of resources or slow patient recruitment. The remaining results focus on the remaining 6 centers (**Figure 1**).

Figure 1. Flow Diagram 28 Centers assessed for eligibility 22 Excluded 3 Did not meet criteria 17 Refused 2 Withdrew during control phase 6 Centers randomized 6 Centers randomized to 6 Centers randomized to control phase intervention phase 4148 Patients screened for eligibility 3951 Patients screened for eligibility **1026** For NRS ≥ 5 **968** For NRS ≥ 5 **851** For NRS 2 to 4 859 For NRS 2 to 4 3306 Excluded 3229 Excluded 2227 For NRS scores 2162 For NRS scores below 2 below 2 1073 Opted out or early-1067 Opted out or earlystage disease stage disease 6 Missing NRS score 0 Missing NRS score 842 Eligible patients 722 Eligible patients **487** For NRS ≥ 5 **409** For NRS ≥ 5 355 For NRS 2 to 4 313 For NRS 2 to 4 483 Excluded 393 Excluded 77 Could not contact 123 Could not contact 318 Refused 272 Refused 20 With no cancer or 30 With no cancer or non-English speaking non-English speaking 22 Other 14 Other **280** For NRS ≥ 5 **264** For NRS ≥ 5 **79** For NRS 2 to 4 65 For NRS 2 to 4

5/12

A total of 8099 patients were screened from whom 1564 were eligible for either primary or secondary outcome measures. Of these, 754 patients gave consent to participate in the study. These 6 centers were randomized to receive the intervention in order resulting in 359 patients in the control phase and 329 in the intervention phase, with 544 contributing to primary outcome measurement. In terms of the missing values in the follow-up period (ie, week 2 and week 4), the patterns of missing were not associated with the main demographic variables suggesting missing completely at random.

# **Baseline Characteristics**

Baseline characteristics for samples of patients contributing data to primary and secondary outcomes are summarized in **Table 1**. For NRS scores of 5 or more, there was a higher proportion of males in the control group than the intervention group (150 of 280 participants [54%] vs 121 of 264 participants [46%]) and a higher proportion of people with breast cancer in the intervention group 61 of 264 participants (23%) vs 46 of 280 participants (16%) in the control group. However, there were no statistically significant differences in the characteristics of patients between phases.

The duration of phases varied between centers, with the control phases lasting between 84 and 255 days and the intervention phases between 120 and 338 days. Initially, the training phase was planned to last 3 weeks. However, this was not possible at 2 centers because of time constraints, with the result that they transitioned from control to intervention phases within a few days only. The sustainability phase was also abandoned because of lack of resources at centers to continue the intervention after resourcing from the project team was removed. The stepped-wedge timeline is shown in **Figure 2**.

### **Outcomes**

For the primary outcome, namely a reduction in the pain score by 30% among those with a score of 5 or more on the NRS on worst pain at week 1, there was no significant difference between the control and intervention phases. The proportions were similar with 31 of 280 participants (11.9%) in the control phase and 30 of 264 participants (11.8%) in the intervention. After adjusting for the potential confounding variables, the results indicated no significant increase in the odds of the outcome (OR, 1.12; 95% CI, 0.79-1.60). Results on the secondary outcome measures are also

Table 1. Baseline Patients' Characteristics at Control and Intervention Phases and Comparisons of the Total Between Phases (N = 688)<sup>a</sup>

	Participants, No. (%)						
Characteristic	Control phase (n = 359)			Intervention phase (n = 329)			
	NRS≥5 (n = 280)	NRS 2-4 (n = 79)	Total	NRS≥5 (n = 264)	NRS 2-4 (n = 65)	Total	
Male	150 (54)	46 (58)	196 (55)	121 (46)	34 (52)	155 (47)	
Female	130 (46)	33 (42)	163 (45)	143 (54)	31 (48)	174 (53)	
Age, mean (SD)	63.9 (12.6)	65.1 (11.5)	64.2 (12.1)	63.4 (12.9)	64.0 (11.7)	63.6 (12.7)	
NESB	23 (8)	0	23 (6)	27 (10)	0	27 (8)	
Cancer type							
Breast	46 (16)	16 (20)	62 (17)	61 (23)	10 (15)	71 (22)	
Lung	33 (12)	13 (16)	46 (13)	35 (13)	7 (11)	42 (13)	
Gastrointestinal	53 (19)	10 (13)	63 (18)	47 (18)	16 (25)	63 (19)	
Genitourinary	48 (17)	19 (24)	67 (19)	44 (17)	12 (18)	56 (17)	
Head and neck	21 (8)	3 (4)	24 (7)	11 (4)	3 (5)	14 (4)	
Hematologic	8 (3)	2 (3)	10 (3)	10 (4)	2 (3)	12 (4)	
Others	50 (18)	14 (18)	64 (18)	44 (17)	13 (20)	57 (17)	
Not recorded	21 (8)	2 (3)	23 (6)	12 (5)	2 (3)	15 (5)	
Worst NRS score, mean (SD)	6.8 (1.5)	3.1 (0.9)	5.0 (2.6)	6.8 (1.4)	3.0 (0.8)	4.9 (2.6)	
Mean NRS score, mean (SD)	5.9 (1.2)	2.9 (0.8)	3.5 (2.1)	5.9 (1.0)	2.9 (0.8)	3.2 (2.1)	

Abbreviations: NESB, Non-English-speaking background; Not recorded, diagnosis was not recorded; NRS, numeric rating scale.

<sup>&</sup>lt;sup>a</sup> No comparison results were statistically significant.

summarized in Table 2. As shown, there were no significant differences in the outcome measures between phases. Regarding the secondary outcome measures heiQ and CES, the responses were small with many missing data rendering the analyses unfeasible.

Changes in pain scores within each phase are reported in Table 3. Mean average pain improved by an SD of 0.5 or more at all time points in both phases except week 1 in the intervention phase. Mean worst pain improved by 0.5 SD at week 4 in both phase. Table 3 shows the changes in mean (SD) NRS scores from baseline at different time points of follow-up by phases and results on pairwise comparisons.

Fidelity to the intervention was lower than anticipated. Two sites had 2 audit cycles and the other sites had 1. Completion rates of health professional training varied between sites from 12% to 74%. The proportion of patients receiving written information (5 sites) was 30% (20%-44%) vs 22% (2%-30%) in the control arm.




Table 2. Results Obtained on the Primary and Secondary Outcomes

Outcomes of the study	Control phase, mean (SD)	Intervention phase	Results on comparison, Z-value <sup>a</sup>	P value
Primary outcome				
Pain score reduction of 30% among those with ≥5 NRS on worst pain at week 1	31 (11.9)	30 (11.8)	OR, 1.12 (95% CI, 0.79-1.60)	.51
Secondary outcome				
Worst pain NRS score at week 1 follow-up mean (SD)	4.4 (2.4)	4.3 (2.3)	0.28	.78
NRS score at week 1 follow-up, mean (SD)	3.0 (1.9)	2.5 (1.8)	-0.96	.34
Total QLQ-C15-PAL score at week 1 follow-up	14.6 (1.9)	14.6 (1.8)	0.11	.92
Worst pain NRS score at week 2 follow-up, mean (SD)	4.7 (2.7)	4.2 (2.4)	-0.89	.37
NRS score at week 2 follow-up, mean (SD)	3.1 (2.0)	2.7 (1.8)	-0.70	.48
Total QLQ-C15-PAL score at week 2 follow-up, mean (SD)	14.5 (2.2)	14.9 (1.8)	1.82	.07
Worst pain NRS score at week 4 follow-up, mean (SD)	4.4 (2.5)	4.3 (2.7)	0.36	.72
NRS score at week 4 follow-up, mean (SD)	2.9 (1.7)	2.8 (2.1)	-0.58	.55
Total QLQ-C15-PAL score at week 4 follow-up, mean (SD)	14.8 (1.9)	14.7 (1.8)	-0.11	.91

Abbreviations: NRS, numeric rating score; OR, odds ratio; QLQ-C15-PAL, Quality of Life Questionnaire Core 15 Palliative Care.

Table 3. Changes in Pain NRS Scores From Baseline at Different Time Points of Follow-up by Phases and Results on Pairwise Comparisons

	Changes in scores for participants in control phase, mean (SD)		Changes in scores for participants in intervention phase, mean (SD)		
Week of follow-up	Worst score	Average score	Worst score	Average score	
1	-0.70 (2.44) <sup>a</sup>	-2.15 (2.18) <sup>a</sup>	-0.01 (2.27)	-1.04 (2.32) <sup>a</sup>	
2	-0.70 (2.67) <sup>a</sup>	-2.32 (2.38) <sup>a</sup>	-0.43 (2.17)	-1.93 (2.09) <sup>a</sup>	
4	-0.89 (2.54) <sup>a</sup>	-2.41 (2.40) <sup>a</sup>	-0.88 (2.67) <sup>a</sup>	-2.36 (2.55) <sup>a</sup>	

<sup>&</sup>lt;sup>a</sup> P < .001.

7/12

<sup>&</sup>lt;sup>a</sup> Adjusted for cluster effect, age, sex, cancer type, Qstream, information pack, audit cycles, and time spent in the phase.

JAMA Network Open. 2022;5(2):e220060. doi:10.1001/jamanetworkopen.2022.0060

### Discussion

In this adequately powered, stepped wedge, cluster randomized trial, guideline implementation strategies at the level of the clinical service, health professional, and patient did not deliver a 30% or greater improvement in patients' pain compared with usual care. This finding was despite the combined use of a conceptual framework, <sup>26</sup> evidence-based implementation strategies, and services with clinical champions. <sup>15,16,27,31</sup> Participants in both phases reported improved mean and worst pain scores over time. However, the lack of a comparison group where no screening was offered means we cannot conclude whether this improvement was because of screening, usual pain management, or a Hawthorne effect. <sup>32</sup>

There are several potential explanations for the lack of effect difference between groups. Interventions added to usual care are inadequate without dedicated resourcing and focus. The fidelity to the intervention may have been insufficient in terms of the number of rounds of audit and feedback and proportions of staff and patients who completed the spaced education module. The implementation of these strategies as a multicomponent intervention may have required a more intensive approach and more effective engagement with the cancer service management than was achieved. We had used a behavior change framework to design the interventions.<sup>26</sup> The use of an explicit implementation framework, such as PARIHS (Promoting Action on Research Implementation in Health Services), would likely have helped us to better understand and act upon the implementation issues arising from this evaluation trial as it was conducted.<sup>33</sup> Centers participating had high baseline knowledge of pain guidelines and high proportions of complex patients with refractory pain. Barriers to pain management previously identified, including participation in pain management intervention being seen as a lower priority and related trials as less important a contribution to the knowledge base than those concerned with curative treatment, may have been contributing factors. 19 The team is currently analyzing qualitative data collected during the trial to better understand the challenges to fidelity and how this might be improved in the future.

Our finding that pain improved during both phases mirrors the findings of at least one other study that compared screening alone with screening plus a pain treatment protocol.<sup>34</sup> Optimistically, it may be that improvements in the screening condition resulted from clinicians using the data during consultations without the need for prompting introduced during the Intervention phase. However, previous randomized clinical trials of screening interventions vs no screening in outpatient services have rarely demonstrated improvements in pain scores, especially in palliative care.<sup>35</sup> Also, the current study used a paper-based screening system, which has largely been replaced in more recent literature by electronic systems due to their better potential for integrating with electronic health records and therefore influencing processes of care.<sup>36</sup> We used paper-based screening because technical problems with electronic screening encountered when piloting the intervention at a single center suggested it would not be feasible to implement across multiple centers during the study period.<sup>9</sup> Additionally, patient recall over weeks may vary.<sup>37</sup> The strategies targeted the service but not the health system policies and procedures for the collection of PROMs, and this system-level change is needed for embedding screening into routine care.

Given evidence that collecting and acting on (PROMs) improve outcomes,<sup>38</sup> the incidental observation that these were not routinely collected in cancer centers requires further attention. The PROM collection was seen as research rather than a clinical practice tool and changing this mindset among clinicians is an important direction for person-centered care.<sup>39</sup>

Patient education is effective in pain management and should be embedded in workflow for cancer patient care. <sup>40</sup> A major barrier to optimal patient education was the lack of nurses in ambulatory care. Adequate staffing with nurses in ambulatory care would provide rapid, focused assessment of patients, develop long-term nurse, patient, and family relationships, and deliver patient education. <sup>41</sup>

#### Limitations

This study had limitations. Methodological limitations included the fact that there was poor participation for secondary outcomes at week 1 because many potential participants did not receive the information and consent documents by mail in the requisite time frame. The fact that center staff and the research team could not be blinded may have biased the patient selection and outcome data collection. Response bias was less likely because patients were only minimally aware of the study aims and design. There was also potential for selection bias because of patients who chose not to complete screening or found rating pain difficult with numeric rather than categorical scales. It may be that phone collection of PROMs resulted in different results than in-person collection; however, studies in other populations have found comparable results.<sup>42</sup>

# **Conclusions**

In this study, pain management guideline implementation strategies did not significantly improve pain-related outcomes for outpatients with advanced cancer compared with usual care. This likely reflects limited intervention uptake by centers, perhaps because of a lack of additional dedicated resources. Oncology ambulatory care services require adequate resources to provide routine pain screening, patient and staff education, and quality improvement cycles.

#### **ARTICLE INFORMATION**

Trial Registration: clinicaltrials.gov Identifier: ACTRN12615000064505.

Accepted for Publication: December 29, 2021.

Published: February 21, 2022. doi:10.1001/jamanetworkopen.2022.0060

**Open Access:** This is an open access article distributed under the terms of the CC-BY License. © 2022 Lovell MR et al. *JAMA Network Open*.

Corresponding Author: Melanie R. Lovell, PhD, Palliative Care Department, HammondCare, 97-115 River Rd, Greenwich, NSW 2065, Australia (mlovell@hammond.com.au).

Author Affiliations: Palliative Care Department, HammondCare, Greenwich, Australia (Lovell); Northern Clinical School, Sydney Medical School, Sydney, Australia (Lovell, Clarke, Clark); IMPACCT Centre—Improving Palliative, Aged and Chronic Care through Clinical Research and Translation University of Technology Sydney, Sydney, Australia (Lovell, Phillips, Luckett, Lam, Davidson, Cheah, Currow, Lee, Read, Agar); Patricia Ritchie Centre for Cancer Care and Research, University of Sydney, Sydney, Australia (Boyle); Johns Hopkins University School of Nursing, Baltimore, Maryland (Davidson); Deakin University, Geelong, Deakin Health Economics, Institute for Health Transformation, School of Health and Social Development, Victoria, Australia (McCaffrey); Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia (Currow); University of Sydney, Sydney, Australia (Shaw); The University of Notre Dame Australia, School of Nursing Sydney and St Vincent's Health Network Sydney, Sydney, Australia (Hosie); Flinders Medical Centre and Flinders University, Adelaide, Australia (Koczwara); Royal North Shore Hospital, St Leonards, Australia (Clarke, Clark); Concord Centre for Palliative Care, Concord Repatriation General Hospital, Sydney, NSW, Australia (Lee, Stockler); University of Sydney, Concord Clinical School, Australia (Lee); Palliative Care Department, South East Sydney Local Health District, Southern Sector, Sydney Australia (Sheehan); Palliative Care Department, Western Health, University of Melbourne, Melbourne, Australia (Spruijt); Palliative Care Department, Westmead Hospital, Westmead, Sydney, Australia (Allsopp); Department of Palliative Care, Peter Macallum Cancer Centre, Melbourne, Australia (Clinch); University of Wollongong, Wollongong, Australia (Davidson).

**Author Contributions**: Dr Lovell had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Lovell, Phillips, Luckett, Lam, Boyle, Davidson, Currow, Shaw, Clarke, Spruijt, Agar.

Acquisition, analysis, or interpretation of data: Lovell, Phillips, Luckett, Lam, Davidson, Cheah, McCaffrey, Shaw, Hosie, Koczwara, Clarke, Stockler, Lee, Sheehan, Allsopp, Clinch, Clark, Read, Agar.

Drafting of the manuscript: Lovell, Phillips, Luckett, Lam, Davidson, Cheah, Koczwara, Sheehan, Spruijt, Read, Agar. Critical revision of the manuscript for important intellectual content: Lovell, Phillips, Luckett, Lam, Boyle, Davidson, Cheah, McCaffrey, Currow, Shaw, Hosie, Koczwara, Clarke, Stockler, Lee, Spruijt, Allsopp, Clinch, Clark, Agar.

9/12

Statistical analysis: Lam, Cheah, Stockler.

Obtained funding: Lovell, Phillips, Luckett, Boyle, Shaw, Agar.

Administrative, technical, or material support: Lovell, Phillips, Luckett, Davidson, Cheah, McCaffrey, Shaw, Hosie, Koczwara, Clarke, Stockler, Lee, Sheehan, Read, Agar.

Supervision: Lovell, Phillips, Luckett, Boyle, Koczwara, Agar.

Conflict of Interest Disclosures: Dr Phillips reported receiving grants from National Breast Cancer Foundation during the conduct of the study. Dr Luckett reported receiving grants from National Breast Cancer Foundation (Australia) during the conduct of the study. Dr McCaffrey reported receiving grants from National Breast Cancer Foundation during the conduct of the study. Dr Currow reported receiving a patent for Mayne Pharma with royalties paid. Dr Shaw reported receiving grants from National Health and Medical Research Centre was a competitively funded grant during the conduct of the study. Dr Hosie reported receiving grants from National Breast Cancer Foundation during the conduct of the study. Dr Sheehan reported receiving grants from Cancer Institute of New South Wales during the conduct of the study. Dr Agar reported receiving grants from National Breast Cancer Foundation during the conduct of the study and receiving personal fees from Astra Zeneca outside the submitted work. No other disclosures were reported.

Funding/Support: This research was supported by a grant from the National Breast Cancer Foundation.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 2.

**Additional Contributions:** We thank Sally Fielding, MPH (IMPACCT), Linda Richards, BPharm, and Layla Edwards, BAppPH (IMPACCT), for project management and research assistance.

#### REFERENCES

- 1. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. *J Pain Symptom Manage*. 2016;51(6):1070-1090.e9. doi:10.1016/j.jpainsymman.2015.12.340
- 2. Chapman EJ, Edwards Z, Boland JW, et al. Practice review: evidence-based and effective management of pain in patients with advanced cancer. *Palliat Med.* 2020;34(4):444-453. doi:10.1177/0269216319896955
- **3.** Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain*. 2012;13(8):715-724. doi:10.1016/j.jpain.2012.03.009
- **4**. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. *J Pain Symptom Manage*. 2003;25(1):9-18. doi:10.1016/S0885-3924(02)00597-3
- **5**. Party AACPMGW. Cancer pain management in adults. Cancer Council Australia. Published 2020. Accessed December 23, 2020. https://wiki.cancer.org.au/australia/Guidelines:Cancer\_pain\_management.
- **6.** Jacobsen PB, Snyder CF. Improving pain assessment and management in routine oncology practice: the role of implementation research. *J Clin Oncol.* 2018;36(13):1272-1274. doi:10.1200/JCO.2018.78.2110
- 7. Luckett T, Davidson PM, Green A, Boyle F, Stubbs J, Lovell M. Assessment and management of adult cancer pain: a systematic review and synthesis of recent qualitative studies aimed at developing insights for managing barriers and optimizing facilitators within a comprehensive framework of patient care. *J Pain Symptom Manage*. 2013;46(2):229-253. doi:10.1016/j.jpainsymman.2012.07.021
- **8**. Luckett T, Davidson PM, Green A, et al. Development of a cancer pain self-management resource to address patient, provider, and health system barriers to care. *Palliat Support Care*. 2019;17(4):472-478. doi:10.1017/S1478951518000792
- 9. Lovell M, Birch MR, Luckett T, et al. Screening and audit as service-level strategies to support implementation of Australian guidelines for cancer pain management in adults: a feasibility study. *Pain Manag Nurs*. 2019;20(2): 113-117. doi:10.1016/j.pmn.2018.05.004
- 10. van den Beuken-van Everdingen MHJ, van Kuijk SMJ, Janssen DJA, Joosten EAJ. Treatment of pain in cancer: towards personalised medicine. *Cancers (Basel)*. 2018;10(12):10. doi:10.3390/cancers10120502
- 11. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care: a systematic review of controlled trials. *J Clin Oncol*. 2014;32(14):1480-1501. doi:10.1200/JCO.2013.53.5948
- 12. Luckett T, Butow PN, King MT. Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. *Psychooncology*. 2009;18(11):1129-1138. doi:10.1002/pon.1545

- **13**. Oldenmenger WH, Geerling JI, Mostovaya I, et al. A systematic review of the effectiveness of patient-based educational interventions to improve cancer-related pain. *Cancer Treat Rev.* 2018;63:96-103. doi:10.1016/j.ctrv. 201712.005
- **14.** Phillips JL, Heneka N, Bhattarai P, Fraser C, Shaw T. Effectiveness of the spaced education pedagogy for clinicians' continuing professional development: a systematic review. *Med Educ.* 2019;53(9):886-902. doi:10.1111/medu.13895
- **15**. Phillips JL, Heneka N, Hickman L, Lam L, Shaw T. Impact of a novel online learning module on specialist palliative care nurses' pain assessment competencies and patients' reports of pain: Results from a quasi-experimental pilot study. *Palliat Med.* 2014;28(6):521-529. doi:10.1177/0269216314527780
- **16.** Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. *Cochrane Database Syst Rev.* 2012(6):CD000259. doi:10.1002/14651858.CD000259.pub3
- 17. Fallon M, Walker J, Colvin L, Rodriguez A, Murray G, Sharpe M; Edinburgh Pain Assessment and Management Tool Study Group. Pain management in cancer center inpatients: a cluster randomized trial to evaluate a systematic integrated approach-the Edinburgh pain assessment and management tool. *J Clin Oncol.* 2018;36(13):1284-1290. doi:10.1200/JCO.2017.76.1825
- **18.** Du Pen SL, Du Pen AR, Polissar N, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. *J Clin Oncol.* 1999;17(1):361-370. doi:10.1200/JC0.1999.17.1.361
- 19. Cleeland CS, Portenoy RK, Rue M, et al. Does an oral analgesic protocol improve pain control for patients with cancer: an intergroup study coordinated by the Eastern Cooperative Oncology Group. *Ann Oncol.* 2005;16(6): 972-980. doi:10.1093/annonc/mdi191
- **20**. Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. *Expert Rev Pharmacoecon Outcomes Res.* 2004;4(5):581-585. doi:10.1586/147371674.5.581
- 21. Maunsell E, Lauzier S, Brunet J, Pelletier S, Osborne RH, Campbell HS. Health-related empowerment in cancer: validity of scales from the Health Education Impact Questionnaire. *Cancer*. 2014;120(20):3228-3236. doi:10. 1002/cncr.28847
- **22**. Groenvold M, Petersen MA, Aaronson NK, et al; EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. *Eur J Cancer*. 2006;42(1):55-64. doi:10.1016/j.ejca.2005.06.022
- 23. Al-Janabi H, Flynn TN, Coast J. Estimation of a preference-based carer experience scale. *Med Decis Making*. 2011;31(3):458-468. doi:10.1177/0272989X10381280
- 24. Hemming K, Taljaard M, McKenzie JE, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. *BMJ*. 2018;363:k1614. doi:10.1136/bmj.k1614
- 25. Luckett T, Phillips J, Agar M, et al. Protocol for a phase III pragmatic stepped wedge cluster randomised controlled trial comparing the effectiveness and cost-effectiveness of screening and guidelines with, versus without, implementation strategies for improving pain in adults with cancer attending outpatient oncology and palliative care services: the Stop Cancer PAIN trial. *BMC Health Serv Res.* 2018;18(1):558. doi:10.1186/s12913-018-3318-0
- **26**. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. *Implement Sci.* 2011;6(1):42. doi:10.1186/1748-5908-6-42
- 27. Kerfoot BP, Turchin A, Breydo E, Gagnon D, Conlin PR. An online spaced-education game among clinicians improves their patients' time to blood pressure control: a randomized controlled trial. *Circ Cardiovasc Qual Outcomes*. 2014;7(3):468-474. doi:10.1161/CIRCOUTCOMES.113.000814
- **28**. Basch E, Trentacosti AM, Burke LB, et al. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective. *Cancer*. 2014;120(5):761-767. doi:10.1002/cncr.28470
- **29**. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe: grading pain severity by its interference with function. *Pain*. 1995;61(2):277-284. doi:10.1016/0304-3959(94) 00178-H
- **30**. Yennurajalingam S, Kang JH, Hui D, Kang DH, Kim SH, Bruera E. Clinical response to an outpatient palliative care consultation in patients with advanced cancer and cancer pain. *J Pain Symptom Manage*. 2012;44(3): 340-350. doi:10.1016/j.jpainsymman.2011.09.014
- **31**. Luckett T, Davidson PM, Green A, et al. Development of a cancer pain self-management resource to address patient, provider, and health system barriers to care. *Palliat Support Care*. 2019;17(4):472-478. doi:10.1017/S1478951518000792
- 32. Sedgwick P. Treatment effects and placebo effects. BMJ. 2015;350:h267. doi:10.1136/bmj.h267

- **33**. Stetler CB, Damschroder LJ, Helfrich CD, Hagedorn HJ. A guide for applying a revised version of the PARIHS framework for implementation. *Implement Sci.* 2011;6:99-99. doi:10.1186/1748-5908-6-99
- **34.** Williams JE, Peacock J, Gubbay AN, et al. Routine screening for pain combined with a pain treatment protocol in head and neck cancer: a randomised controlled trial. *Br J Angesth*. 2015;115(4):621-628. doi:10.1093/bia/aev263
- **35**. Etkind SN, Daveson BA, Kwok W, et al. Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference: a systematic review. *J Pain Symptom Manage*. 2015;49(3): 611-624. doi:10.1016/j.jpainsymman.2014.07.010
- **36**. Jensen RE, Rothrock NE, DeWitt EM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. *Med Care*. 2015;53(2):153-159. doi:10.1097/MLR. 0000000000000289
- **37**. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The accuracy of pain and fatigue items across different reporting periods. *Pain*. 2008;139(1):146-157. doi:10.1016/j.pain.2008.03.024
- **38**. Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. *Am Soc Clin Oncol Educ Book*. 2018;38(38):122-134. doi:10.1200/EDBK 200383
- **39**. Schmidt T, Valuck T, Perkins B, et al. Improving patient-reported measures in oncology: a payer call to action. *J Manag Care Spec Pharm.* 2021;27(1):118-126. doi:10.18553/jmcp.2020.20313
- **40**. Scher C, Meador L, Van Cleave JH, Reid MC. Moving beyond pain as the fifth vital sign and patient satisfaction scores to improve pain care in the 21st century. *Pain Manag Nurs*. 2018;19(2):125-129. doi:10.1016/j.pmn.2017. 10.010
- **41**. Haas SS, Swan BA, Haynes T. *Developing Ambulatory Care Registered Nurse Competencies for Care Coordination and Transition Management*. College of Nursing Faculty Papers and Presentations. 2013;61.
- **42**. Kose O, Deniz G, Ozcan H, Guler F. A comparison of telephone interview versus on-site completion of Lysholm knee score in patients who underwent arthroscopic ACL reconstruction: are the results equivalent? *Eur J Orthop Surg Traumatol*. 2015;25(6):1069-1072.

**SUPPLEMENT 1.** 

**Trial Protocol** 

**SUPPLEMENT 2.** 

**Data Sharing Statement**